Target Name: MIR4724
NCBI ID: G100616248
Review Report on MIR4724 Target / Biomarker Content of Review Report on MIR4724 Target / Biomarker
MIR4724
Other Name(s): hsa-mir-4724 | microRNA 4724 | hsa-miR-4724-3p | hsa-miR-4724-5p | mir-4724 | MicroRNA 4724

MIR4724: A Potential Drug Target and Biomarker for Chronic Pain

Chronic pain is a major public health issue, affecting millions of people worldwide. The persistent and often severe nature of chronic pain can have a significant impact on an individual's quality of life, and can even lead to disability and malnutrition. In addition, chronic pain can also have significant economic and societal costs. Therefore, there is a need for effective treatments that can alleviate or manage chronic pain.

MIR4724 is a potential drug target and biomarker that has been identified as a potential therapeutic approach for the treatment of chronic pain. In this article, we will discuss the potential mechanisms of MIR4724 and its potential as a drug target and biomarker for the treatment of chronic pain.

Potential Mechanisms of MIR4724

MIR4724 is a small non-coding RNA molecule that has been shown to play a role in the regulation of gene expression and has been identified as a potential drug target for the treatment of chronic pain. MIR4724 has been shown to promote the expression of genes involved in pain perception and synthesis, such as TrkA, TrkB, and MrIP, which are involved in the production of pain-related neurotransmitters, such as corticotoxin and opioids.

In addition, MIR4724 has also been shown to regulate the activity of GABA, a neurotransmitter that has been shown to have anti-inflammatory and pain-relieving effects. MIR4724 has been shown to inhibit the activity of GABA-gated channels, which are involved in the regulation of GABA levels and its effects on pain perception.

MIR4724 has also been shown to play a role in the regulation of pain modulation, by modulating the activity of nociceptors, which are cells that respond to pain stimuli and enhance pain perception. MIR4724 has been shown to increase the activity of nociceptors, which can lead to increased pain perception, and to decrease the activity of descending pain modulatory systems, such as the hypothalamic-pituitary-adrenal (HPA) axis and the descending pain modulatory system (DPS), which can lead to decreased pain perception.

Potential as a Drug Target

MIR4724 has been shown to be a potential drug target for the treatment of chronic pain due to its role in the regulation of pain perception and synthesis. MIR4724 has been shown to promote the production of pain-related neurotransmitters, such as corticotoxin and opioids, and to regulate the activity of GABA, which is involved in the regulation of pain modulation.

MIR4724 has also been shown to play a role in the regulation of pain modulation by modulating the activity of nociceptors and the HPA axis. These findings suggest that MIR4724 may be an effective drug target for the treatment of chronic pain.

Potential as a Biomarker

MIR4724 has also been shown to be a potential biomarker for the treatment of chronic pain. The regulation of pain perception and synthesis is a complex process that involves the production and regulation of multiple genes and molecules. MIR4724 has been shown to play a role in the regulation of this process, which suggests that it may be a useful biomarker for the diagnosis and assessment of chronic pain.

MIR4724 has been shown to increase the activity of genes involved in

Protein Name: MicroRNA 4724

The "MIR4724 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about MIR4724 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets

MIR4725 | MIR4726 | MIR4727 | MIR4728 | MIR4729 | MIR4730 | MIR4731 | MIR4732 | MIR4733 | MIR4734 | MIR4735 | MIR4736 | MIR4737 | MIR4738 | MIR4739 | MIR4740 | MIR4741 | MIR4742 | MIR4745 | MIR4746 | MIR4747 | MIR4749 | MIR4750 | MIR4751 | MIR4752 | MIR4753 | MIR4754 | MIR4755 | MIR4756 | MIR4757 | MIR4758 | MIR4759 | MIR4760 | MIR4761 | MIR4762 | MIR4763 | MIR4764 | MIR4765 | MIR4766 | MIR4767 | MIR4768 | MIR4769 | MIR4770 | MIR4771-1 | MIR4771-2 | MIR4772 | MIR4773-1 | MIR4773-2 | MIR4774 | MIR4775 | MIR4776-1 | MIR4776-2 | MIR4777 | MIR4778 | MIR4779 | MIR4780 | MIR4781 | MIR4782 | MIR4783 | MIR4784 | MIR4785 | MIR4786 | MIR4787 | MIR4789 | MIR4790 | MIR4791 | MIR4793 | MIR4794 | MIR4795 | MIR4796 | MIR4797 | MIR4798 | MIR4799 | MIR4800 | MIR4802 | MIR4803 | MIR4804 | MIR483 | MIR484 | MIR485 | MIR486-1 | MIR486-2 | MIR487A | MIR487B | MIR488 | MIR489 | MIR490 | MIR491 | MIR492 | MIR493 | MIR494 | MIR495 | MIR496 | MIR497 | MIR497HG | MIR498 | MIR4999 | MIR499A | MIR499B | MIR5000